Thursday, May 21, 2015 4:30:27 PM
Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine.
Sub-category:
Leukemia
Category:
Leukemia, Myelodysplasia, and Transplantation
Meeting:
2015 ASCO Annual Meeting
Abstract No:
7007
Citation:
J Clin Oncol 33, 2015 (suppl; abstr 7007)
Author(s): Hanna Jean Khoury, Robert Collins, William G. Blum, Patrick J. Stiff, Jane Lebkowski, Edward Wirth, Kevin Nishimoto, John F. DiPersio; Winship Cancer Institute of Emory University, Atlanta, GA; The University of Texas Southwestern Medical Center, Dallas, TX; The Ohio State University Wexner Medical Center, Columbus, OH; Loyola Univ Med Ctr, Maywood, IL; Asterias Biotherapeutics, Menlo Park, CA; Washington University School of Medicine in St. Louis, St. Louis, MO
Abstract Disclosures
Abstract:
Background: A phase II clinical trial was conducted in which subjects with AML were administered a telomerase-based dendritic cell immunotherapy (AST-VAC1; hTERT-DCs). The hTERT-DCs were prepared from leukapheresis collections from 33 subjects and were transfected with an mRNA encoding telomerase (hTERT) and the lysosomal sorting signal, LAMP-1, which enhances immunostimulatory activity. hTERT is essential for maintaining the proliferative capacity of tumor cells. Methods: AML patients were eligible to receive hTERT-DCs if they were in CR1 or CR2 with intermediate or high risk cytogenetics or if they were in early relapse with < 20% marrow blasts. The hTERT-DCs were prepared after induction therapy and before or after completion of consolidation cycles. The hTERT-DCs were administered as 6 weekly followed by 6 biweekly intradermal injections. Results: Twenty-one patients (median age: 55) in complete remission (16 CR1 and 3 CR2) and or early relapse (2) received at least 3 injections of the hTERT-DCs. Only one grade 3 or 4 adverse event, (idiopathic thrombocytopenia), possibly related to the immunotherapy was observed during the first year. The two patients who were vaccinated during early relapse progressed rapidly and did not receive the full dosing regimen of hTERT-DCs. Of the 19 patients that were in CR, 14 received all 12 doses of hTERT-DCs. Fifty-eight percent (11/19) developed cellular immune responses to hTERT as assessed by peptide ELISpot analysis. Eleven of 19 patients (median follow-up 52 mos.) are still in remission as of last follow-up; seven developed detectable cellular immune responses to hTERT. Of the 19 CR patients, 7 were = 60 yo at the time of hTERT-DC immunotherapy. Four of 7 patients = 60 yo remain relapse free 52-59 months post DC-hTERT immunotherapy with all four developing immune responses to hTERT. The three patients that received DC-hTERT while in CR2 were in remission as of their last follow-up of 24, 50 and 59 months with two having hTERT immune responses. Conclusions: The results suggest that immunotherapy with hTERT-DCs is safe, can stimulate an immune response to telomerase, and may provide anti-tumor immune responses even in high risk patients with AML Clinical trial information: NCT00510133
http://abstract.asco.org/156/AbstView_156_148041.html
Recent LCTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/07/2024 10:17:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:10:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 10:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 02:30:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 02:27:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 11:58:18 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/08/2024 11:57:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/06/2024 02:25:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:20:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/06/2024 02:00:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 12:08:49 AM
- Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies • AllPennyStocks.com • 11/16/2023 09:21:00 PM
- Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies • AllPennyStocks.com • 11/16/2023 09:21:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/13/2023 09:19:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:10:32 PM
- Small Company Working on Big Breakthrough in Treating Spinal Cord Injuries • AllPennyStocks.com • 10/11/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 09:01:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:16:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:10:12 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 07/27/2023 08:15:41 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM